Abbott Laboratories ABT announces its next round of earnings Wednesday. Here is Benzinga's everything-that-matters guide for the Q3 earnings announcement.
Earnings and Revenue
Analysts covering Abbott Laboratories modeled for quarterly EPS of 75 cents on revenue of $7.65 billion.
In the same quarter last year, Abbott Laboratories reported EPS of 66 cents on revenue of $6.83 billion. The Wall Street estimate would represent a 13.64-percent increase in the company's earnings. Revenue would be have grown 12.02 percent from the same quarter last year. Here's how the company's reported EPS has stacked up against analyst estimates in the past:
| Quarter | Q2 2018 | Q1 2018 | Q4 2017 | Q3 2017 |
| EPS Estimate | 0.71 | 0.58 | 0.73 | 0.65 |
| EPS Actual | 0.73 | 0.59 | 0.74 | 0.66 |
Stock Performance
Over the last 52-week period, shares are up 25.71 percent. Given that these returns are generally positive, long-term shareholders are probably happy going into this earnings release.
Analysts have adjusted their estimates higher for EPS and revenues over the past 90 days. The most common rating by analysts on Abbott Laboratories stock is a Neutral. The strength of this rating has maintained conviction over the past three months.
Conference Call
Abbott Laboratories' Q3 conference call is scheduled to begin at 9:00 a.m. ET and can be accessed here: https://edge.media-server.com/m6/p/4nnf35op
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
